Acinetobacter Pneumonia Therapeutics Market Size

Acinetobacter Pneumonia Therapeutics Market size is evaluated at USD 496.9 million in 2024 and is projected to reach USD 1.1 billion by the end of 2037, growing at around 6.4% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of acinetobacter pneumonia therapeutics is estimated at USD 528.7 million.

The acinetobacter pneumonia therapeutics market growth trajectory is attributed to increasing prevalence of Acinetobacter pneumonia bacterial infection. According to a 2021 study on the prevalence of multidrug-resistant Acinetobacter baumannii, the prevalence of Acinetobacter baumannii was 3.37% and the overall mortality rate was 40.81%. The multi-drug resistance characteristics of these bacteria is increasing demands for advanced therapeutics options such as novel antibiotics, combination therapies, and antimicrobial peptides.

In June 2021, a report published in the National Library of Medicine (NLM) highlighted baumannii to be widespread in Asia and the U.S. For instance, in May 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment for pneumonia induced by hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) called Xacduro. Growing government and private sector funding for antimicrobial resistance research is poised to fuel the acinetobacter pneumonia therapeutics market growth.

The World Health Organization (WHO) classifies Acinetobacter species on top of the list of critical bacterial pathogens that pose threats to human health, which pushes for a global need for advanced treatment and therapeutics. Additionally, COVID-19 pandemic highlighted the urgent need for effective treatment for Acinetobacter induced pneumonia cases which are on the rise. Healthcare systems across the world require novel solutions to risks posed by the Acinetobacter baumannii strain of bacteria. With rising investments in the healthcare sector and increasing research on bacterial strains, the global acinetobacter pneumonia therapeutics market is projected to maintain steady growth by the end of the forecast period.